BR112015010318A2 - Variantes de albumina - Google Patents

Variantes de albumina

Info

Publication number
BR112015010318A2
BR112015010318A2 BR112015010318A BR112015010318A BR112015010318A2 BR 112015010318 A2 BR112015010318 A2 BR 112015010318A2 BR 112015010318 A BR112015010318 A BR 112015010318A BR 112015010318 A BR112015010318 A BR 112015010318A BR 112015010318 A2 BR112015010318 A2 BR 112015010318A2
Authority
BR
Brazil
Prior art keywords
variants
albumin
albumin variants
relates
polynucleotides
Prior art date
Application number
BR112015010318A
Other languages
English (en)
Inventor
Cameron Jason
Delahay Karen
Erik Nielsen Jens
Plumridge Andrew
Terje Andersen Jan
Original Assignee
Albumedix As
Novozymes Biopharma Dk As
Albumedix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albumedix As, Novozymes Biopharma Dk As, Albumedix Ltd filed Critical Albumedix As
Publication of BR112015010318A2 publication Critical patent/BR112015010318A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

VARIANTES DE ALBUMINA. A invenção se refere a variantes de uma albumina progenitora, as variantes tendo meia-vida plasmática alterada comparado com a albumina precursora. A presente invenção se refere também a polinucleotídeos que codificam as variantes; construtos de ácido nucleico, vetores e células hospedeiras que compreendem os polinucleotídeos; e métodos de uso das variantes.
BR112015010318A 2012-11-08 2013-11-08 Variantes de albumina BR112015010318A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12191856 2012-11-08
PCT/EP2013/073426 WO2014072481A1 (en) 2012-11-08 2013-11-08 Albumin variants

Publications (1)

Publication Number Publication Date
BR112015010318A2 true BR112015010318A2 (pt) 2017-08-22

Family

ID=47137625

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010318A BR112015010318A2 (pt) 2012-11-08 2013-11-08 Variantes de albumina

Country Status (13)

Country Link
US (3) US20140128326A1 (pt)
EP (1) EP2917233A1 (pt)
JP (2) JP6487328B2 (pt)
KR (1) KR20150082422A (pt)
CN (1) CN105452290A (pt)
AU (2) AU2013343503B2 (pt)
BR (1) BR112015010318A2 (pt)
CA (1) CA2890766A1 (pt)
GB (1) GB2512156A (pt)
IL (1) IL238185B (pt)
MX (1) MX2015005363A (pt)
RU (1) RU2670063C2 (pt)
WO (1) WO2014072481A1 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
MX2012004793A (es) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Variantes de albumina.
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SI2771022T1 (sl) 2011-10-11 2020-12-31 Viela Bio, Inc. CD40L-specifična ogrodja pridobljena iz TN3 in postopki njihove uporabe
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
EP2825556B1 (en) 2012-03-16 2018-01-03 Albumedix A/S Albumin variants
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2833892A4 (en) 2012-04-02 2016-07-20 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
CA2890766A1 (en) * 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
RU2663587C2 (ru) * 2013-03-06 2018-08-07 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Клетки-хозяева и способы использования
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
AU2014329452B2 (en) 2013-10-03 2019-06-20 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
TW201609812A (zh) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 最佳化之跨物種特異性雙特異性單鏈抗體構築體
CA2977675A1 (en) * 2015-03-12 2016-09-15 Medimmune, Llc Method of purifying albumin-fusion proteins
CN116063541A (zh) 2015-04-17 2023-05-05 安进研发（慕尼黑）股份有限公司 用于cdh3和cd3的双特异性抗体构建体
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EP3337816B1 (en) * 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
WO2017112847A1 (en) 2015-12-22 2017-06-29 Albumedix A/S Improved protein expression strains
SG11201805497QA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US10738293B2 (en) 2016-03-02 2020-08-11 Novozymes A/S Cellobiohydrolase variants and polynucleotides encoding same
US11965189B2 (en) 2016-03-24 2024-04-23 Novozymes A/S Cellobiohydrolase variants and polynucleotides encoding same
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
WO2017210684A1 (en) * 2016-06-03 2017-12-07 New York University Methods and reagents for modulating macrophage phenotype
US20210333279A1 (en) 2016-11-04 2021-10-28 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
WO2018094181A1 (en) 2016-11-21 2018-05-24 Novozymes A/S Yeast cell extract assisted construction of dna molecules
CA3057989C (en) * 2017-04-05 2023-03-21 Korea Research Institute Of Bioscience And Biotechnology Nk cell-activating fusion protein, nk cell, and pharmaceutical composition including same
CN111032871A (zh) 2017-06-20 2020-04-17 阿尔布梅迪克斯医疗有限公司 改良的表达蛋白质的菌株
WO2018234518A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG MODULATION OF IMMUNOGENICITY OF FVIII BY VWF TRONQUÉ
RS63101B1 (sr) 2017-08-03 2022-04-29 Amgen Inc Interleukin-21 muteini i metode lečenja
TWI731264B (zh) 2017-09-08 2021-06-21 美商安進公司 Kras g12c抑制劑以及其使用方法
CN109553684A (zh) * 2017-09-25 2019-04-02 中国科学院过程工程研究所 一种纳米载体蛋白及其制备方法和应用
JP7465210B2 (ja) 2017-11-29 2024-04-10 シーエスエル リミティド 虚血－再灌流障害の治療又は予防方法
EP3737694B1 (en) 2018-01-12 2023-03-01 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
KR20210013091A (ko) 2018-05-16 2021-02-03 시에스엘 리미티드 가용성 보체 수용체 1형 변이체 및 이의 용도
MX2021001221A (es) 2018-07-30 2021-06-23 Amgen Res Munich Gmbh Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
KR20210042117A (ko) 2018-08-03 2021-04-16 암젠 리서치 (뮌헨) 게엠베하 Cldn18.2 및 cd3에 대한 항체 작제물
AU2019336940A1 (en) 2018-09-06 2021-03-11 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2021044362A1 (en) 2019-09-06 2021-03-11 Novartis Ag Therapeutic fusion proteins
EP3819007A1 (en) 2019-11-11 2021-05-12 Amgen Research (Munich) GmbH Dosing regimen for anti-bcma agents
US20230000774A1 (en) 2019-12-04 2023-01-05 Albumedix Limited Methods and compositions produced thereby
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
KR20220153587A (ko) 2020-03-12 2022-11-18 버베리안 노딕 에이/에스 폭스바이러스 안정성을 개선하는 조성물
US20230146593A1 (en) 2020-03-12 2023-05-11 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
CA3183693A1 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
CN116829183A (zh) 2020-09-16 2023-09-29 美国安进公司 施用治疗剂量的双特异性t细胞接合分子治疗癌症的方法
KR20230098334A (ko) 2020-11-06 2023-07-03 암젠 리서치 (뮌헨) 게엠베하 Cldn6 및 cd3에 선택적으로 결합하는 폴리펩디드 작제물
EP4240407A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Antigen binding domain with reduced clipping rate
EP4240767A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Polypeptide constructs binding to cd3
EP4243936A1 (en) 2020-11-10 2023-09-20 Amgen Inc. Methods for administering a bcma x cd3 binding molecule
CN113717873B (zh) * 2021-09-27 2023-04-14 四川大学 一种多重耐受性酿酒酵母菌株及其构建方法和应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
GB9019919D0 (en) 1990-09-12 1990-10-24 Delta Biotechnology Ltd Purification of proteins
US2714586A (en) 1951-06-25 1955-08-02 Phillips Petroleum Co Washing urea and thiourea containing adducts
JPS4983148A (pt) 1972-12-16 1974-08-09
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPS60169498A (ja) 1984-02-10 1985-09-02 Kyowa Hakko Kogyo Co Ltd 成人ｔ細胞白血病ウイルス抗原ペプチド誘導体
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
BR8806573A (pt) 1987-04-09 1989-10-31 Delta Biotechnology Ltd Vetor de levedo
ES2076939T3 (es) 1987-08-28 1995-11-16 Novo Nordisk As Lipasa recombinante de humicola y procedimiento para la produccion de lipasas recombinantes de humicola.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
IL88326A (en) 1987-11-18 1993-03-15 Gist Brocades Nv Purification of serum albumin
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE4000939A1 (de) 1990-01-15 1991-07-18 Brem Gottfried Prof Dr Dr Verfahren zur antikoerpergewinnung
JP3230091B2 (ja) 1990-06-25 2001-11-19 ウェルファイド株式会社 ヒト血清アルブミンの着色抑制方法
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE4226971C2 (de) 1992-08-14 1997-01-16 Widmar Prof Dr Tanner Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5824837A (en) 1993-07-22 1998-10-20 Merck & Co., Inc. Expression of human interleukin-1β in a transgenic animal
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
CN1230997A (zh) 1996-07-17 1999-10-06 津莫吉尼蒂克斯公司 甲醇毕赤酵母的转化
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US7053190B2 (en) 1997-03-07 2006-05-30 Human Genome Sciences, Inc. Secreted protein HRGDF73
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US5948609A (en) 1997-12-03 1999-09-07 Carter; Daniel C. Oxygen-transporting albumin-based blood replacement composition and blood volume expander
EP1030931A4 (en) 1998-08-06 2004-05-26 Syntron Biores Inc URIC ACID TEST DEVICE HAVING A STABILIZED URICASE REACTIVE COMPOSITION
WO2000039327A1 (en) 1998-12-23 2000-07-06 Human Genome Sciences, Inc. Peptidoglycan recognition proteins
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
CA2372338A1 (en) 1999-05-17 2000-11-23 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
EP1178786A4 (en) 1999-05-21 2006-03-01 American Bioscience Inc PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE
ATE312176T1 (de) 2000-03-22 2005-12-15 Octagene Gmbh Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
CA2419894A1 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh Process for high throughput screening of cpg-based immuno-agonist/antagonist
AU2002245204A1 (en) 2000-10-25 2002-07-24 Genzyme Corporation Methods for treating blood coagulation disorders
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
PL209550B1 (pl) 2000-12-07 2011-09-30 Lilly Co Eli Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulinoniezależną i kompozycja do leczenia pacjentów z otyłością
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
AUPR446701A0 (en) 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
US6949691B2 (en) 2001-06-15 2005-09-27 New Century Pharmaceuticals Inc. Human albumin animal models for drug evaluation, toxicology and immunogenicity studies
ATE375388T1 (de) 2001-07-27 2007-10-15 Us Gov Health & Human Serv Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden
CN1405182A (zh) 2001-08-10 2003-03-26 中国人民解放军军事医学科学院生物工程研究所 血清白蛋白与粒细胞集落刺激因子的融合蛋白
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
CN101166762A (zh) 2002-02-07 2008-04-23 达尔塔生物技术有限公司 白蛋白融合的Kunitz结构域肽
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
US6995933B1 (en) 2002-04-30 2006-02-07 Western Digital Technologies, Inc. Disk drive for optimizing write current settings relative to drive operating characteristics and ambient temperature readings
WO2003102136A2 (en) 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
GB0217347D0 (en) 2002-07-26 2002-09-04 Univ Edinburgh Novel albumins
WO2004013287A2 (en) 2002-08-02 2004-02-12 Human Genome Sciences, Inc. Antibodies against c3a receptor
AU2003295644A1 (en) 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
KR20050121673A (ko) 2003-02-17 2005-12-27 업퍼톤 리미티드 담체, 표적화제 및 조영제를 포함하는 의료 영상화용접합체
GB0305989D0 (en) 2003-03-15 2003-04-23 Delta Biotechnology Ltd Agent
WO2004082640A2 (en) 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
EP1618131A2 (en) 2003-04-15 2006-01-25 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
US20050079546A1 (en) 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
WO2005082423A2 (en) 2003-11-18 2005-09-09 Beth Israel Deaconess Medical Center Serum albumin conjugated to fluorescent substances for imaging
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
JP4649954B2 (ja) 2003-12-26 2011-03-16 ニプロ株式会社 抗菌作用が増強されたアルブミン
US7166577B2 (en) 2003-12-26 2007-01-23 Nipro Corporation Albumin having enhanced antimicrobial activity
KR100671005B1 (ko) 2004-01-15 2007-01-18 고려대학교 산학협력단 Ｐａｈ 노출 여부 진단용 바이오 마커 단백질
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
RU2369404C2 (ru) * 2004-02-09 2009-10-10 Хьюман Дженом Сайенсиз, Инк. Слитые белки альбумина
JP4492156B2 (ja) 2004-03-03 2010-06-30 ニプロ株式会社 血清アルブミンドメインを含む蛋白質
US20060018859A1 (en) 2004-07-16 2006-01-26 Carter Daniel C Modified human serum albumin with reduced or eliminated affinity to chemical or biological contaminants at Cys 34
US20060051859A1 (en) 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
CA2593922A1 (en) 2004-12-22 2006-06-29 Novozymes A/S Recombinant production of serum albumin
EP1831375B1 (en) 2004-12-23 2014-07-16 Novozymes Biopharma DK A/S Gene expression technique
JPWO2006073195A1 (ja) 2005-01-07 2008-06-12 敏一 吉川 糖尿病の予知・診断方法および糖尿病予知・診断用キット
US20060178301A1 (en) 2005-02-04 2006-08-10 Mathias Jurs Albumin-fused ciliary neurotrophic factor
EP1879920A2 (en) 2005-04-29 2008-01-23 The Jackson Laboratory Fcrn antibodies and uses thereof
GB0512707D0 (en) 2005-06-22 2005-07-27 Delta Biotechnology Ltd Gene expression technique
JP2009504157A (ja) 2005-08-12 2009-02-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
CA2562249A1 (en) 2005-10-20 2007-04-20 University Of Ottawa Heart Institute Anf analogue
CN101384623B (zh) 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP3896090B1 (en) 2006-06-14 2022-01-12 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
JP5670634B2 (ja) 2006-07-13 2015-02-18 アッパートン リミティド タンパク質性物質の粒子の製造方法
JP4983148B2 (ja) 2006-08-18 2012-07-25 ニプロ株式会社 糖鎖含有アルブミン、その製造方法およびその用途
JP5840345B2 (ja) 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用
US20100129846A1 (en) 2006-12-07 2010-05-27 Power3 Medical Products, Inc. Isoform specificities of blood serum proteins and their use as differentially expressed protein biomarkers for diagnosis of breast cancer
EP2594583A1 (en) 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrin variants and conugates
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CA2611540C (en) 2007-11-09 2017-05-30 Nipro Corporation Sugar chain-containing albumin as a drug carrier to the liver
MX343594B (es) 2007-12-21 2016-11-11 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
AU2009243187C1 (en) 2008-04-28 2015-12-24 President And Fellows Of Harvard College Supercharged proteins for cell penetration
US20110151490A1 (en) 2008-07-18 2011-06-23 Oragenics, Inc. Compositions for the Detection and Treatment of Colorectal Cancer
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
JP5496220B2 (ja) 2008-12-05 2014-05-21 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー アルブミン結合ペプチド介在性の疾患標的化
EP2370473B1 (en) 2008-12-10 2016-05-11 The Scripps Research Institute Production of carrier-peptide conjugates using chemically reactive unnatural amino acids
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
EP2419120A4 (en) 2009-04-08 2016-01-06 Univ California HUMAN PROTEIN CONCERNS WITH CONTROLLED SERUM PHARMACOKINETICS
US9221886B2 (en) 2009-04-28 2015-12-29 President And Fellows Of Harvard College Supercharged proteins for cell penetration
US8232067B2 (en) 2009-05-29 2012-07-31 Brigham & Women's Hospital, Inc. Disrupting FCRN-albumin interactions
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
KR101286721B1 (ko) 2009-06-05 2013-07-16 한국과학기술연구원 폴리-시스테인 펩티드 융합 재조합 알부민 및 이의 제조방법
KR20120097481A (ko) 2009-07-20 2012-09-04 내셔날 쳉쿵 유니버시티 사람 혈청 알부민(ＨＳＡ)의 변이체와 컨쥬게이션된 αｖβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도
EP2456787A4 (en) 2009-07-24 2013-01-30 Univ Leland Stanford Junior CYTOKINE COMPOSITIONS AND METHODS OF USE
EP2464974A1 (en) 2009-08-10 2012-06-20 UCL Business PLC Functionalisation of solid substrates
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
KR20120093932A (ko) 2009-10-10 2012-08-23 일레븐 바이오테라피틱스, 아이엔씨. Ｉｌ－１７ 패밀리 사이토카인 조성물들 및 용도들
MX2012004793A (es) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Variantes de albumina.
JP5739908B2 (ja) 2009-12-23 2015-06-24 國立成功大學Ｎａｔｉｏｎａｌ Ｃｈｅｎｇ Ｋｕｎｇ Ｕｎｉｖｅｒｓｉｔｙ 血管形成関連の眼疾患の処置のための組成物および方法
CN101875693B (zh) 2010-01-22 2012-07-18 成都正能生物技术有限责任公司 具备抗血管生成活性的白蛋白变异体及其制备方法
AU2011218294A1 (en) 2010-02-16 2012-08-30 Medimmune, Llc HSA-related compositions and methods of use
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
WO2011161127A1 (en) 2010-06-21 2011-12-29 Medimmune, Llc Protease variants of human neprilysin
JP2013538566A (ja) 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
US20130225496A1 (en) * 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
WO2012112188A1 (en) * 2011-02-15 2012-08-23 Medimmune, Llc Hsa-related compositions and methods of use
JP5641536B2 (ja) * 2011-03-15 2014-12-17 日本パーカライジング株式会社 固定砥粒ソーワイヤー用電着液
KR20140027307A (ko) 2011-05-05 2014-03-06 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP2825556B1 (en) 2012-03-16 2018-01-03 Albumedix A/S Albumin variants
WO2014005596A1 (en) 2012-07-03 2014-01-09 Aarhus Universitet Modified payload molecules and their interactions and uses
US8757798B2 (en) 2012-08-31 2014-06-24 Cody Air LLC Eyewear frame
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
EP3044232A1 (en) 2013-09-13 2016-07-20 Novozymes Biopharma DK A/S Albumin variants
US10208102B2 (en) 2013-11-01 2019-02-19 University Of Oslo Albumin variants and uses thereof
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates

Also Published As

Publication number Publication date
US20150210752A1 (en) 2015-07-30
IL238185A0 (en) 2015-05-31
US20200102367A1 (en) 2020-04-02
JP2015535300A (ja) 2015-12-10
US10501524B2 (en) 2019-12-10
RU2015121693A (ru) 2016-12-27
CA2890766A1 (en) 2014-05-15
IL238185B (en) 2019-09-26
GB201319754D0 (en) 2013-12-25
WO2014072481A1 (en) 2014-05-15
AU2013343503B2 (en) 2017-12-14
KR20150082422A (ko) 2015-07-15
JP2019048821A (ja) 2019-03-28
GB2512156A (en) 2014-09-24
JP6487328B2 (ja) 2019-03-20
US20140128326A1 (en) 2014-05-08
AU2013343503A1 (en) 2015-04-30
MX2015005363A (es) 2015-11-06
AU2018201136A1 (en) 2018-03-08
US10934341B2 (en) 2021-03-02
RU2670063C2 (ru) 2018-10-17
CN105452290A (zh) 2016-03-30
EP2917233A1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
BR112015010318A2 (pt) Variantes de albumina
BR112014018679A2 (pt) variantes de albumina
BR112017023975A2 (pt) variantes de alfa-amilase e polinucleotídeos codificando as mesmas
BR112018072282A2 (pt) composições detergentes e usos das mesmas
AR113177A2 (es) Polipéptidos que tienen actividad de lisozima y polinucleótidos que los codifican
AR122864A2 (es) Variantes de lipasa y polinucleótidos que las codifican
CR20140565A (es) Proteínas de fusión de interleuquina 10 y usos de las mismas
EP3741849A3 (en) Protease variants and polynucleotides encoding same
WO2015014790A3 (en) Protease variants and polynucleotides encoding same
MX2019005158A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
MX353621B (es) Variantes de alfa-amilasa.
IN2014CN00597A (pt)
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
PE20142406A1 (es) Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
WO2015024739A3 (en) Detergent composition comprising protease variants
BR112015024119A2 (pt) polipeptídeos tendo atividade de fosfolipase a e polinucleotídeos que os codificam
MX2014002415A (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EP4253534A3 (en) Alpha-amylase variants and polynucleotides encoding same
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
BR112015021753A2 (pt) promotores de levedura provenientes de pichia pastoris
MX2015000312A (es) Polipeptidos que tienen actividad lipasa y polinucleotidos que los codifican.
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
EP3321360A3 (en) Alpha-amylase variants and polynucleotides encoding same
BR112015030655A2 (pt) Variantes de xilanase e polinucleótidos que codificam as mesmas

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B12F Other appeals [chapter 12.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ALBUMEDIX A/S (DK)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALBUMEDIX LTD (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements